About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Part 2: Potential Concerns and Challenges for P&T Committees
P&T committee members need a lot more information before they can evaluate the efficacy and safety, interchangeability, and cost-effectiveness of biosimilar products for inclusion on formularies.
C. Lee Ventola, MS
A Review of Treatment Options With a Focus on Pharmacological Approaches
Oral contraceptives, antidiabetes drugs, and statins are some of the therapies used to address the symptoms of this complex hormonal condition. Weight loss and surgery may also be beneficial as non-drug options.
Uche Anadu Ndefo, PharmD, BCPS; Angie Eaton, PharmD; and Monica Robinson Green, PharmD, BCPS, BCACP
A Potentially Serious and Underreported Problem
There have been many published reports of possible cases of drug-induced pancreatitis. In addition, some disease states and patient characteristics predispose particular populations to the development of this condition. Three case histories are presented.
Michele B. Kaufman, PharmD, RPh
Therapies for hepatitis C include sofosbuvir; an interferon-free triple regimen; and an investigational agent, MK-5172. Ramucirumab for gastric and gastroesophageal junction cancers and an everolimus/exemestane combination for breast cancer are also discussed.
Matthew Grissinger, RPh, FASCP
FDA approvals, drug indications, and updates
Extended-release carbinoxamine maleate oral suspension (Karbinal ER) for allergic rhinitis; brinzolamide 1.0%/brimonidine tartrate 0.2% ophthalmic suspension (Simbrinza) for open-angle glaucoma and ocular hypertension; and cysteamine bitartrate (Procysbi) for nephropathic cystinosis
Marvin M. Goldenberg, PhD, RPh, MS
A Condition of Involuntary Crying or Laughing
Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect
Martin Paspe Cruz, PharmD, CGP, BCPP